Details of the Drug

General Information of Drug (ID: DMGZV7U)

Drug Name

ISIS 14803

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis C virus infection	1E51.1	Discontinued in Phase 2	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antisense

Drug Type

Antisense drug

Structure

3D MOL is unavailable

2D MOL

#Ro5 Violations (Lipinski): 5

Molecular Weight (mw)

6515

Logarithm of the Partition Coefficient (xlogp)

-6.5

Rotatable Bond Count (rotbonds)

116

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

144

Chemical Identifiers

Formula: C200H257N72O103P19S19
IUPAC Name: 1-[5-[[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[2-[[[2-[[[2-[[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[2-[[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[2-[[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
Canonical SMILES: CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5CC(OC5COP(=S)(O)OC6CC(OC6COP(=S)(O)OC7CC(OC7COP(=S)(O)OC8CC(OC8COP(=S)(O)OC9CC(OC9COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1CO)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)N1C=C(C(=NC1=O)N)C)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=NC1=O)N)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=NC1=O)N)C)O
InChI: InChI=1S/C200H257N72O103P19S19/c1-74-32-253(190(288)228-154(74)201)126-14-87(358-376(299,395)318-44-106-85(274)12-125(338-106)258-37-79(6)170(275)247-195(258)293)107(339-126)46-320-379(302,398)364-94-21-133(261-40-82(9)173(278)250-198(261)296)347-115(94)53-327-391(314,410)372-101-28-141(269-70-224-150-166(269)236-186(211)243-179(150)284)355-123(101)61-335-393(316,412)374-103-30-143(271-72-226-152-168(271)238-188(213)245-181(152)286)353-121(103)57-331-383(306,402)362-91-18-130(257-36-78(5)158(205)232-194(257)292)341-109(91)48-323-387(310,406)368-97-24-136(264-65-219-145-159(206)215-63-217-161(145)264)349-117(97)55-330-382(305,401)361-90-17-129(256-35-77(4)157(204)231-193(256)291)343-111(90)50-325-390(313,409)371-100-27-140(268-69-223-149-165(268)235-185(210)242-178(149)283)352-120(100)59-333-385(308,404)367-96-23-135(263-42-84(11)175(280)252-200(263)298)348-116(96)54-328-392(315,411)373-102-29-142(270-71-225-151-167(270)237-187(212)244-180(151)285)356-124(102)62-336-394(317,413)375-104-31-144(272-73-227-153-169(272)239-189(214)246-182(153)287)354-122(104)60-334-386(309,405)366-95-22-134(262-41-83(10)174(279)251-199(262)297)346-114(95)52-326-388(311,407)369-98-25-137(265-66-220-146-160(207)216-64-218-162(146)265)350-118(98)56-329-381(304,400)360-89-16-128(255-34-76(3)156(203)230-192(255)290)340-108(89)47-321-380(303,399)363-93-20-132(260-39-81(8)172(277)249-197(260)295)345-113(93)51-322-378(301,397)359-88-15-127(254-33-75(2)155(202)229-191(254)289)342-110(88)49-324-389(312,408)370-99-26-139(267-68-222-148-164(267)234-184(209)241-177(148)282)351-119(99)58-332-384(307,403)365-92-19-131(259-38-80(7)171(276)248-196(259)294)344-112(92)45-319-377(300,396)357-86-13-138(337-105(86)43-273)266-67-221-147-163(266)233-183(208)240-176(147)281/h32-42,63-73,85-144,273-274H,12-31,43-62H2,1-11H3,(H,299,395)(H,300,396)(H,301,397)(H,302,398)(H,303,399)(H,304,400)(H,305,401)(H,306,402)(H,307,403)(H,308,404)(H,309,405)(H,310,406)(H,311,407)(H,312,408)(H,313,409)(H,314,410)(H,315,411)(H,316,412)(H,317,413)(H2,201,228,288)(H2,202,229,289)(H2,203,230,290)(H2,204,231,291)(H2,205,232,292)(H2,206,215,217)(H2,207,216,218)(H,247,275,293)(H,248,276,294)(H,249,277,295)(H,250,278,296)(H,251,279,297)(H,252,280,298)(H3,208,233,240,281)(H3,209,234,241,282)(H3,210,235,242,283)(H3,211,236,243,284)(H3,212,237,244,285)(H3,213,238,245,286)(H3,214,239,246,287)
InChIKey: GHSDIAMGUUDZLY-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 22833937
DrugBank ID: DB05803
TTD ID: D0VB9J

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatitis C virus Internal ribosome entry site messenger RNA (HCV IRES mRNA)	TTXWCK2	NOUNIPROTAC	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009426)
2	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.